Swiss Medical Technology Industry 2012

The internationally escalating pressure of costs, pricing and competition, growing regulatory requirements, scarce expert capacities and the strong Franc leave the Swiss medical technology sector faced with enormous challenges. Valuable parts of the supply chain threaten to migrate out of Switzerland. The Swiss Medical Technology Industry 2012 report reveals where the journey leads. The Medical Cluster, Medtech Switzerland and IMS Consulting Group present the results from over 320 firm interviews and reveal possible solutions.

With over 1,600 companies, 51,000 full-time positions, a turnover of around 12.5 billion CHF contributing to 2.1 per cent of the Swiss GDP, and an export volume of nearly 11 billion CHF, the Swiss medical technology industry is still doing well. By international comparisons, Switzerland as a region is still a global "hot spot" for medical technology. Until now, Switzerland has had a great advantage in that the proximity of the entire medtech value chain has allowed the industry to support itself and work together to fuel the growth of the entire Swiss medtech industry. However, circumstances are rapidly changing.

Growth in the single digits - shrinking margins
The 2012 SMTI report reveals an increasing trend of slow growth compared to the last two studies. The average growth expectancy now rests at 5.9 per cent for 2012 and at 6.6 per cent for 2013, or almost half the growth rate seen in previous years. According to the authors of the study, growth will remain in the single-digit figures in the near future. The average growth in the medtech workforce over the last two years continues to be positive at 3 per cent, but still remains lower than expected. For many companies it appears that the golden days are over. "Five to ten years ago the margins amounted to, on average, over 10 per cent, today they come only within the single-digit per cent range," emphasise both authors of the study, Patrick Dümmler, Medtech Switzerland, and Beatus Hofrichter, IMS Consulting Group.

Small firms, especially from the supply industry, suffer the most from growing international pressure due to pricing and competition. The strength of the Swiss franc is named as another of the three greatest challenges for the sector Thus despite the lower limit on the exchange rate, industry export has had to absorb a currency appreciation of 23 % since the beginning of 2010 when compared to the Euro. According to the survey, 81 per cent of all SMTI firms are affected by this problem.

Exchange rate problems intensify foreign investments
To better safeguard against exchange rate fluctuations, 15 per cent of all companies are planning investments over the next three years in production facilities abroad where the economic environment is more favourable (natural hedging). Suppliers and manufacturers will also increasingly procure their outlay and investment goods outside of Switzerland. In addition, more and more Swiss medical technology firms are converting to foreign ownership. In Switzerland the tight budgets in the Swiss healthcare system, administrative expenditures and bureaucracy place increasing strain on the companies as a result of growing regulatory requirements. This all leads to the threat of impending migration of the supply chain. "There is an urgent need for negotiation to prevent the Swiss medical technology ecosystem from breaking apart," the authors warn.

Not only external factors, but also internal structural weaknesses accelerate the trend towards consolidation however. Companies are lacking in management skills and expert knowledge. In particular, marketing, compliance, regulatory affairs and QM specialists are strongly needed.

Forming national clusters and operating pools
In over 86 per cent of all responses, marketing development and market knowledge were considered an important topic, followed by increase in profitability. Currently the sector focuses on commercial and operative excellence. Despite more intense competition, medical technology companies concentrate too little on the strategic development of new business models and marketing channels.

In view of the developments mentioned, and according to the authors of the study, it is high time to act both for the sector and for the region as a whole. The medical technology industry must take on an active role in market consolidation. The authors of the study see potential a solutions in the formation of national clusters and product and/or service pools, within which the suppliers of healthcare services and products develop innovative solutions together to support the Swiss supply chain.

SMTI 2012 report for download:
http://www.medical-cluster.ch/smti

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...